Herceptin Approved For Every-Three-Week Dosing In Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Trastuzumab is cleared for adjuvant treatment in HER2-positive node-positive and node-negative breast cancer as a single agent or combined with hormonal therapy.